"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to IMVT. [ FAQ on what and how to ask] For non-IMVT questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Eric Venker M.D., Pharm.D.
Headquarter: 1000 Park Forty Plaza, Suite 210, Durham, NC, United States, 27713
Industry: Biotechnology, Investment Track: Biotech - Autoimmune - Medium, Employees: 362
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
My Watchlist
